asco 2015 investor event

ASCO 2015 Investor EventMay 31, 2015

Forward Looking Statements and Adjusted Financial Information

This presentation contains forward-looking statements, which are generally statements that are nothistorical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,”“believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking, , , p , , p gstatements are based on management’s current plans, estimates, assumptions and projections, andspeak only as of the date they are made. We undertake no obligation to update any forward-lookingstatement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict andare generally beyond our control Actual results or outcomes may differ materially from those impliedare generally beyond our control. Actual results or outcomes may differ materially from those impliedby the forward-looking statements as a result of the impact of a number of factors, many of whichare discussed in more detail in our Annual Report on Form 10-K and our other reports filed with theSecurities and Exchange Commission.

In addition to unaudited financial information prepared in accordance with U.S. GAAP, thispresentation also contains adjusted financial measures that we believe provide investors andmanagement with supplemental information relating to operating performance and trends thatfacilitate comparisons between periods and with respect to projected information. These adjustedmeasures are non-GAAP and should be considered in addition to but not as a substitute for themeasures are non GAAP and should be considered in addition to, but not as a substitute for, theinformation prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items thatmanagement does not believe affect our basic operations and that do not meet the GAAP definitionof unusual or non-recurring items. Other companies may define these measures in different ways.Further information relevant to the interpretation of adjusted financial measures, and reconciliations

f th dj t d fi i l t th t bl GAAP b f d

2

of these adjusted financial measures to the most comparable GAAP measures, may be found onCelgene’s website at www.Celgene.com in the “Investor Relations” section.

Jackie Fouse, PhDPresident, Global Hematology & Oncology

Agenda

Welcome/ Introduction Jackie Fouse, PhD

Clinical Update Jay Backstrom, MD

Celgene and Immuno-Oncology Rob Hershberg, MD PhD

W U J ki F PhDWrap-Up Jackie Fouse, PhD

Q&A

4

ASCO 2015: Presentations Across Our Portfolio

TOPIC ABX LEN POM AZA CC 486 Durvalumab Other TotalTOPIC ABX LEN POM AZA CC-486 Durvalumab (MEDI4736)

Other Total

Breast Cancer 8 8

Lung Cancer 2 2

Pancreatic Cancer 7 1 1 9

MM 11 3 3 17MM 11 3 3 17

Myeloid Disease 2 1 1 1 5

Lymphoma 9 9

Other 6 2 1 2 11

TOTAL 23 22 3 2 3 1 7 61

5

Abstract count includes all studies with a Celgene product

5

Jay Backstrom, MD SVP, Global Hematology & Oncology Clinical R&D

Agenda

Advancing ABRAXANE®1 Advancing ABRAXANE®1 Advancing ABRAXANE®1 Advancing ABRAXANE®1

Ongoing Progress in Myeloma2 Ongoing Progress in Myeloma2

Expanding into Lymphoma3 Expanding into Lymphoma3

7

Agenda




8

Treatments in Pancreatic Cancer

AdjuvantAdjuvant

Neoadjuvant/ Borderline

Neoadjuvant/ Borderline Gemcitabine monotherapyGemcitabine monotherapy

Gemcitabine monotherapyGemcitabine monotherapyAdjuvant(~10K pts)Adjuvant(~10K pts)

Borderline Resectable (~2K pts)


Locally Advanced(~17K pts)


Gemcitabine monotherapyGemcitabine monotherapy

ChemotherapyChemotherapy

1st Line Metastatic(~64K pts)


(~17K pts)(~17K pts)

ABRAXANE®/GemcitabineABRAXANE®/Gemcitabine

2nd Line Metastatic(~26K pts)

2nd Line Metastatic(~26K pts) ChemotherapyChemotherapy

9

Footnote: Patient numbers are estimates of annual treated patients in US and EU G5

9

Clinical Development in Pancreatic Cancer

AdjuvantAdjuvantAdjuvant Adjuvant



Adjuvant(~10K pts)Adjuvant(~10K pts)

Multiple Investigator

Registration StudyAPACT

Registration StudyAPACT





Neoadjuvant studies

Locally advanced LAPACT

Locally advanced LAPACT



(~17K pts)(~17K pts)

Elevated BilirubinElevated Bilirubin

LAPACTLAPACT

>50 AG + novel therapy ongoing



10

Footnote: Patient numbers are estimates of annual treated patients in US and EU G5Celgene-sponsored trials IITs or Cooperative Group trials

10

Pancreatic Cancer Abstracts of Interest at ASCO 2015

Author Abstract Title

Hidalgo #4118 A Phase Ib Study of the Anti-Cancer Stem Cell Agent Demcizumab and Gemcitabine +/- Paclitaxel Protein Bound Particles in Pts with Pancreatic Cancer Poster, Monday

Hingorani #4006 High Response Rate and PFS with PEGPH20 Added to nab-P lit l/G it bi i St IV P i l U t t d P tiPaclitaxel/Gemcitabine in Stage IV Previously Untreated PancreaticCancer Patients with High-HA Tumors: Interim Results of a Randomized Phase II StudyOral, Sunday, 10am

O'Reilly #4114 Safety Pharmacokinetics Pharmacodynamics and Antitumor Activity ofO Reilly #4114 Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity ofNecuparanib Combined with nab-Paclitaxel and Gemcitabine in Patientswith Metastatic Pancreatic Cancer: Phase 1 ResultsPoster, Monday

11




Hingorani #4006 High Response Rate and PFS with PEGPH20 Added to nab-P lit l/G it bi i St IV P i l U t t d P ti

Demcizumab (OncoMed)

Ongoing phase 1b dose escalationPaclitaxel/Gemcitabine in Stage IV Previously Untreated PancreaticCancer Patients with High-HA Tumors: Interim Results of a Randomized Phase II StudyOral, Sunday, 10am

O'Reilly #4114 Safety Pharmacokinetics Pharmacodynamics and Antitumor Activity of

• Ongoing phase 1b dose escalation• Cohorts 4, 5 & 6 received truncated demcizumab(2.5, 3.5 or 5 mg/kg every 2 wks through Day 70) and ABRAXANE® 125 mg/m2 + gemcitabine 1000 mg/m23 of 4 wksO Reilly #4114 Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of

Necuparanib Combined with nab-Paclitaxel and Gemcitabine in Patientswith Metastatic Pancreatic Cancer: Phase 1 ResultsPoster, Monday

ABRAXANE 125 mg/m2 + gemcitabine 1000 mg/m23 of 4 wks

• Treatment was generally well-tolerated with mainly GI and fatigue AEsfatigue AEs• Encouraging clinical activity was observed• Updated data on tolerability and efficacy to be presented

12




Hingorani #4006 High Response Rate and PFS with PEGPH20 Added to nab-P lit l/G it bi i St IV P i l U t t d P ti

ABRAXANE®/gemcitabine emerging as standard-Paclitaxel/Gemcitabine in Stage IV Previously Untreated PancreaticCancer Patients with High-HA Tumors: Interim Results of a Randomized Phase II StudyOral, Sunday, 10am

O'Reilly #4114 Safety Pharmacokinetics Pharmacodynamics and Antitumor Activity of

g g gof-care in 1st line metastatic pancreatic cancer

ABRAXANE®/gemcitabine is the research platform O Reilly #4114 Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of

Necuparanib Combined with nab-Paclitaxel and Gemcitabine in Patientswith Metastatic Pancreatic Cancer: Phase 1 ResultsPoster, Monday

for multiple combinations with novel therapies

13

Treatments in Non-Small Cell Lung Cancer

Metastatic NSCLC (Stage IIIB/IV)Metastatic NSCLC (Stage IIIB/IV)

Non-Squamous (70-75%)Non-Squamous (70-75%) Squamous (25-30%)Squamous (25-30%)

EGFR/ALK+ EGFR/ALK+ PDL1Ineligible

PDL1IneligiblePDL1 High PDL1 High PDL1 Low PDL1 Low PDL1

Ineligible PDL1

Ineligible PDL1 High PDL1 High PDL1 Low PDL1 Low

1st-Line (~290K pts)1st-Line

(~290K pts)ABRAXANE®/carboplatinABRAXANE®/carboplatin

gggg

ChemoChemoTKITKIMaint(~100K pts)

Maint(~100K pts)

Chemo or TKIChemo or TKI

2nd-Line(~140K pts)2nd-Line

(~140K pts)TKI orChemoTKI orChemo Chemo or TKIChemo or TKI

14

Footnote: Patient numbers are estimates of annual treated patients in US and EU G5Source: NCCN Guidelines

14

Ongoing ABRAXANE® NSCLC Trials

Metastatic NSCLC (Stage IIIB/IV)Metastatic NSCLC (Stage IIIB/IV)

Non-Squamous (70-75%)Non-Squamous (70-75%) Squamous (25-30%)Squamous (25-30%)Non-Squamous (70-75%)Non-Squamous (70-75%) Squamous (25-30%)Squamous (25-30%)

EGFR/ALK+ EGFR/ALK+ PDL1Ineligible

PDL1IneligiblePDL1 High PDL1 High PDL1 Low PDL1 Low PDL1

Ineligible PDL1

Ineligible PDL1 High PDL1 High PDL1 Low PDL1 Low

1st Line(~290K pts)

1st Line(~290K pts)

ABRAXANE®

/carbo/MPDL ABRAXANE®

/carbo/MPDL Abound.70+Abound.70+ ABRAXANE®

/carbo/MPDL ABRAXANE®

/carbo/MPDL

TKITKI Abound.PS2Abound.PS2 Abound.PS2Abound.PS2

Abound.sqm

Abound.sqm

Maint (~100K pts)

Maint (~100K pts)

CheckpointCheckpoint Chemo or TKI

Chemo or TKI

Chemo or TKI

Chemo or TKI CheckpointCheckpoint Chemo

or TKIChemo or TKI

2nd Line (~140K pts)2nd Line

(~140K pts)

Chemo or TKI or checkpoint

combo

Chemo or TKI or checkpoint

combo

Chemo or TKI

Chemo or TKI

Chemo/checkpoint or I/O combo or chemo

Chemo/checkpoint or I/O combo or chemo Abound.2LAbound.2L Chemo/checkpoint or I/O

combo of chemoChemo/checkpoint or I/O

combo of chemo

15

Footnote: Patient numbers are estimates of annual treated patients in US and EU G5; Source: NCCN Guidelines

Celgene-sponsored trials Non Celgene-sponsored trials

NSCLC Cancer Abstracts of Interest at ASCO 2015


Kotasek #8045 A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Pts with 1st Line Non-Squamous NSCLCPoster, Monday

Liu #8030 Safety and Efficacy of MPDL3280A (anti-PDL1) in Combination with Platinum-based Doublet Chemotherapy in Patients with Advanced Non-S ll C ll L CSmall Cell Lung Cancer Poster, Monday

16

NSCLC Cancer Abstracts of Interest at ASCO 2015


Kotasek #8045 A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, DemcizumabPemetrexed and Carboplatin in Pts with 1st Line Non-Squamous NSCLCPoster, Monday

Liu #8030 Safety and Efficacy of MPDL3280A (anti-PDL1) in Combination with Platinum-based Doublet Chemotherapy in Patients with Advanced Non-S ll C ll L C

Demcizumab• 1 of 33 (3%) evaluable pts had a RECIST CR, 15

(45%) had a PR and 13 had SD• Potential for explore demcizumab in combination in

Small Cell Lung Cancer Poster, Monday

1st-line non-squamous NSCLC

ABRAXANE® + Atezolizumab• 2 Complete Responses and 6 Partial Responses in2 Complete Responses and 6 Partial Responses in

advanced NSCLC

Phase III trials in 1st-line NSCLC ( )(squamous and non-squamous) with ABRAXANE®/carbo +/- atezolizumab enrolling

17

Treatments in Breast Cancer

HER2+(25%)

HER2+(25%)

HER2-(75%)HER2-(75%)

Neoadjuvant/Neoadjuvant/

HR-(15%)HR-

(15%)HR+

(60%)HR+

(60%)

Neoadjuvant/Adjuvant(~250K pts)


Pre-ChemoMetastaticPre-ChemoMetastatic

Trastuzumab + AC + Taxane

Trastuzumab + AC + Taxane

Not ApplicableNot Applicable

AC + TaxaneAC + Taxane


Taxane/C or AC to hormonal therapyTaxane/C or AC to hormonal therapy

Hormonal therapy +/- mTOR Hormonal therapy +/- mTOR

1st-Line Metastatic1st-Line

Metastatic

Metastatic(~115K pts)Metastatic(~115K pts)

Trastuzumab + Pertuzumab +



ABRAXANE®ABRAXANE®


Hormonal therapy / Capecitabine


pyor CDK

pyor CDK

(~105K pts)(~105K pts)

2nd-Line Metastatic(~75K pts)


TaxaneTaxane CapecitabineCapecitabine

ABRAXANE®ABRAXANE®

18

Footnote: Patient numbers are estimates of annual treated patients in US and EU G5; AC: Anthracycline/cyclophosphamide

Ongoing ABRAXANE® Breast Cancer Trials

HER2+(25%)

HER2+(25%)

HER2-(75%)HER2-(75%)

Neoadjuvant/Neoadjuvant/

HR-(15%)HR-

(15%)HR+

(60%)HR+

(60%)

GEPARSEPTONeoadjuvant/Adjuvant(~250K pts)


Pre-ChemoMetastaticPre-ChemoMetastatic

GEPARSEPTO


ETNA


ADAPT

Hormonal therapy +/- mTOR Hormonal therapy +/- mTOR

1st-Line Metastatic1st-Line

Metastatic

Metastatic(~115K pts)Metastatic(~115K pts)




ABRAXANE® +/-MPDL3280A




pyor CDK

pyor CDK

(~105K pts) (~105K pts)



TaxaneTaxane CapecitabineCapecitabine tnAcitytnAcity

19

Footnote: Patient numbers are estimates of annual treated patients in US and EU G5; AC: Anthracycline/cyclophosphamide

Celgene-sponsored trials IITs or Collaborator Trials

Breast Cancer Abstracts of Interest at ASCO 2015


Gluz #1032 Efficacy of 12 Weeks Neoadjuvant nab-Paclitaxel Combined with Carboplatinum vs. Gemcitabine in Triple-Negative Breast Cancer: WSG-ADAPT TN Randomized Phase II TrialPoster, Saturday

20

Breast Cancer Abstracts of Interest at ASCO 2015


Gluz #1032 Efficacy of 12 Weeks Neoadjuvant nab-Paclitaxel Combined with Carboplatinum vs. Gemcitabine in Triple-Negative Breast Cancer: WSG-ADAPT TN Randomized Phase II TrialPoster, Saturday

ADAPTpCR was in 36% of patients overall; 25% with ABRAXANE®/gem and 49.2% with ABRAXANE®/carbo( 0 006)(p = 0.006)

Updates to GEPARSEPTO and ETNA expected over the next 12 months

Phase III trial in 1st-line TNBC with ABRAXANE®+/-atezolizumab to begin enrollment soon

21

Agenda




22

MM-020: Updated Overall Survival Descriptive Analysis (Rd vs MPT in Newly-Diagnosed Multiple Myeloma)

1Rd

Updated OS per Health Authority request45.5 months median follow-up

(78% of final OS events)

0.8

bilit

y

Rd

MPT

( )

0.4

0.6

rviv

al P

roba

b

0.2

Surv

Study arm Hazard ratioRd vs MPT 0.74 (0.61, 0.89)

Study arm Median OSRd 58.9 mo

MPT 48.5 mo0

0 6 12 18 24 30 36 42 48 54 60 66 72Time, mo

Rd 535 488 457 433 403 366 337 246 156 74 13 0MPT 547 484 448 418 375 347 310 230 130 58 10 0MPT 547 484 448 418 375 347 310 230 130 58 10 0

MPT = melphalan, prednisone, thalidomide; OS = overall survival; Rd = lenalidomide plus low-dose dexamethasone.Hazard ratio is based on stratified Cox-PH model and p value is based on stratified log-rank test.23

MMMM--003: Overall 003: Overall Survival Survival ––ITT Population with POMALYSTITT Population with POMALYST®®/IMNOVID/IMNOVID®®

Median follow-up 10 months

CI, confidence interval; HiDEX, high-dose dexamethasone; HR, hazard ratio; ITT, intent to treat; LoDEX, low-dose dexamethasone; OS, overall survival; POM, pomalidomide.San Miguel J., et al. Lancet Oncol. 2013. DOI: 10.1016/S1470-2045(13)70380-2.

24

MM Abstracts of Interest at ASCO 2015


Holstein #8523 Updated Analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide vs. Placebo Maintenance Therapy after Single Autologous Stem Cell Transplant for Multiple MyelomaPoster, Sunday

Dimopoulos #8525 Effect of Carfilzomib, Lenalidomide, and Dexamethasone vs L lid id d D th i P ti t ith R l d M lti lLenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma by Line of Therapy: Secondary Analysis from an Interim Analysis of the Phase III Study ASPIRE (NCT01080391)Poster, Sunday

Lonial #8508 ELOQUENT 2: A Phase III Randomized Open Label Study ofLonial #8508 ELOQUENT-2: A Phase III, Randomized, Open-Label Study of Lenalidomide/Dexamethasone with/without Elotuzumab in Patients with Relapsed/Refractory Multiple Myeloma Oral, Tuesday 9:45am

Zimmerman #8510 Phase II MMRC Trial of Extended Treatment with CarfilzomibZimmerman #8510 Phase II MMRC Trial of Extended Treatment with Carfilzomib, Lenalidomide, and Dexamethasone plus Autologous Stem Cell Transplantation in Newly Diagnosed Multiple MyelomaOral, Tuesday 10:33am

25

CALGB 100104: REVLIMID® Improved TTP and OS

Median: 53 vs 26 mosHazard ratio 0.54 (p<0.001)

Median: NR vs 76 mosHazard ratio 0.60Hazard ratio 0.60(p=0.001)

Intent-to-treat analysis, data cut-off Nov 2014

26

Research in Multiple Myeloma with Rd Backbone

• ASPIRE (KRd vs RD in RRMM)

Median PFS for pts receiving 1 prior line was 29.6 mos for KRd vs17.6 mos for Rd (hazard ratio [HR]: 0.694; P= .0083). Median PFS for pts ≥ 2 prior lines was 25.8 mos for KRd vs 16.7 mos for Rd (HR: 0.688; P= .0017)

• ELOQUENT-2 (Erd vs RD in RRMM)

Median PFS: ERd 19.4 mos vs. Rd 14.9 mos (HR [95% CI] 0.70 [0.57, 0.85]; p = 0.0004). ORR 79% ERd vs. 66% Rd

• MMRC (KRd + ASCT) in NDMM

Post-Induction Post-Transplant Post-Consolidation

Post-KRdConsolidation

≥ PR% 98 100 100 100≥ VGPR% 78 97 100 100≥ nCR% 14 44 91 100

27

sCR% 10 25 70 86

Agenda




28

REVLIMID® Clinical Plan in Lymphoma Addresses Unmet Need

2nd Relapse 1st Relapse 1L MaintenanceInduction/1L

GCB LRGCB LR patients CD20patients CD20 CHOPCHOP ASCT li ibl ASCTASCT li ibl ASCTHighHigh--risk patients risk patients (Lenalidomide, (Lenalidomide,

BTKi?) BTKi?) REMARCREMARC

NonNon--GCB patientsGCB patientsCD20CD20--CHOPCHOPRR22--CHOPCHOPD

LBC

L GCB LR GCB LR patients CD20patients CD20--CHOPCHOP

GCB HR GCB HR patients CD20patients CD20--CHOPCHOP R(CD20)R(CD20)--ChemoChemo//nnew ew comboscombosASCT ineligible: ASCT ineligible:

R(CD20)R(CD20)--ChemoChemo//new new comboscombos

ASCT eligible: ASCTASCT eligible: ASCT

CD20CD20--nonnon--ChemoChemoCDCD--20 20 ChemoChemo

AUGMENTAUGMENTTMTM

MAGNIFYMAGNIFYTMTM

CD20CD20--nonnon--ChemoChemoIndo

lent RELEVANCERELEVANCE®® (FL)(FL)

CDCD--20 Chemo20 Chemo

CD20 or CD20CD20 or CD20--Combos (R2, BTK) Combos (R2, BTK)

(maint.)(maint.)RIT (consolid.)RIT (consolid.)

Vaccines Vaccines –– TBDTBD

RELEVANCERELEVANCE®® (FL)(FL)

MC

L RR--Chemo Chemo ±± novel agents novel agents (e.g. i(e.g. ibrutinibbrutinib))

MCLMCL--001001MCLMCL--002002

MCL NetworkMCL NetworkRR22

PTC

L RoRo--CHOPCHOPRoRo--CHOPCHOP ISTODAXISTODAX®®ISTODAXISTODAX®®

CHOPCHOP F l tF l t

29

REVLIMID®Existing therapy

P CHOPCHOPOtherOther ChemoChemo

ISTODAX®

FolotynFolotynChemosChemos

Follicular Lymphoma Is a Hematologic Malignancy With a Protracted Disease Course

Availability of novel treatment options and introduction of rituximab maintenance have improved overall survival relative to historical controls

30

Tan D, et al. Blood. 2007;110:Abstract 3428.

Years10 20 30 40

Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH): Meta-Analysis Aims to Identify a Surrogate Endpoint for PFS

CTI

VES

CTI

VES • Establish a novel surrogate efficacy endpoint for PFS in first-line

follicular lymphoma to be used for regulatory decision making• Establish a novel surrogate efficacy endpoint for PFS in first-line

follicular lymphoma to be used for regulatory decision making

OB

JEC

OB

JEC

• Reduce duration of clinical trials to expedite patient access to effective new therapies

• Reduce duration of clinical trials to expedite patient access to effective new therapies

RO

AC

HR

OA

CH • Independently conducted by Mayo Clinic Biostatistics Group (US) in

collaboration with cooperative groups from across the world

• Support from Celgene and Roche

• Independently conducted by Mayo Clinic Biostatistics Group (US) in collaboration with cooperative groups from across the world

• Support from Celgene and Roche

APP

APP

Support from Celgene and Roche

• Followed guidelines and considerations from the FDA

Support from Celgene and Roche

• Followed guidelines and considerations from the FDA

THO

DO

LGY

THO

DO

LGY • A thorough review of all studies conducted in front-line FL was

performed and initially identified > 300 studies of published data

• Patient-level data was obtained from studies that met prespecified selection criteria and where available to perform a meta analysis

• A thorough review of all studies conducted in front-line FL was performed and initially identified > 300 studies of published data

• Patient-level data was obtained from studies that met prespecified selection criteria and where available to perform a meta analysis

31

MET

MET selection criteria and where available to perform a meta-analysis

designed to identify and qualify a surrogate endpointselection criteria and where available to perform a meta-analysis designed to identify and qualify a surrogate endpoint

Lymphoma Abstracts of Interest at ASCO 2015


Sargent #8504 Evaluation of Complete Response Rate at 30 Months as a Surrogate for Progression-Free Survival in First-Line Follicular Lymphoma Studies: Results from the Prospectively Specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Analysis with Individual Patient Data of 3,837 PatientsOral Monday 10:57amOral, Monday, 10:57am

32

Lymphoma Abstracts of Interest at ASCO 2015


Sargent #8504 Evaluation of Complete Response Rate at 30 Months as a Surrogate for Progression-Free Survival in First-Line Follicular Lymphoma Studies: Results from the Prospectively Specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Analysis with Individual Patient Data of 3,837 PatientsOral Monday 10:57am

FLASH Analysis

Trial type Trials, N (pts) R2 WLS (95% CI)a R2 Copula (95% CI)aOral, Monday, 10:57amy ( ) ( ) ( )

Overall 13 (3,837) 0.88 (0.77-0.96) 0.86 (0.72-1.00)Rituximabincluded

9 (2,851) 0.85 (0.62-0.97) 0.80 (0.56-1.00)

No rituximab 4 (986) 0.91 (0.05-1.00) 0.96 (0.90-1.00)Induction 8 (2,207) 0.89 (0.75-0.98) 0.89 (0.74-1.00)Maintenance 5 (1 630) 0 93 (0 84 1 00) 0 89 (0 71 1 00)Maintenance 5 (1,630) 0.93 (0.84-1.00) 0.89 (0.71-1.00)

a R2 values range from 0 (no association) to 1 (perfect prediction)

33

g ( ) (p p )

Solid Tumor Pipeline

Oncology Phase I Phase II Phase III Filing /Approval

ABRAXANE®

BreastNSCLCNSCLCPancreaticAdjuvant pancreaticTriple negative breastBladder

VTX-2337Ovarian cancerOvarian cancerSquamous cell carcinoma

CC-486 (oral aza)Solid tumors

DemcizumabNSCLCPancreaticOvarian

AG-221Solid tumors

Solid Tumor Pipeline

Oncology Phase I Phase II Phase III Filing /Approval

ABRAXANE®

BreastNSCLCNSCLCPancreaticAdjuvant pancreaticTriple negative breastBladder

VTX-2337Ovarian cancer

Advancing Oncology Portfolio

ABRAXANE® t bli h d i h d t t t i l di t t tiOvarian cancerSquamous cell carcinoma

CC-486 (oral aza)Solid tumors

DemcizumabNSCLCPancreatic

• ABRAXANE® established in hard to treat cancers including metastatic pancreatic, lung and metastatic breast

• Expected data read outs over the next 12 monthsOvarian

AG-221Solid tumors

Expected data read outs over the next 12 months • ABRAXANE®/gemcitabine in combination with demcizumab in pancreatic cancer (phase II)• Updated data from GEPARSEPTO in neoadjuvant breast cancer

Demci mab in combination ith carbo/pemetre ed in NSCLC• Demcizumab in combination with carbo/pemetrexed in NSCLC• Motolimod (VTX-2337) in ovarian and head and neck cancers (phase II)

Hematology Pipeline

Hematology Phase I Phase II Phase III Filing /Approval

REVLIMID®

MMMDS deletion 5qMDS non-deletion 5qCLLT-Cell leukemiaNHL - MCLNHL - DLBCLNHL - FLNHL iNHLNHL - iNHL

VIDAZA®

MDSAML

ISTODAX®

CTCL, PTCLPOMALYST®/IMNOVID®

MMCC-486 (oral aza)MDSAML

Sotatercept (ACE-011)MDSDi d bl kf iDiamond blackfan anemiabeta-thalassemiaLuspatercept (ACE-536)MDSbeta-thalassemia

AG-221Heme malignancies

36

Heme malignancies

Hematology Pipeline

Hematology Phase I Phase II Phase III Filing /Approval

REVLIMID®

MMMDS deletion 5qMDS non-deletion 5qCLLT-Cell leukemiaNHL - MCLNHL - DLBCLNHL - FLNHL iNHL

Advancing the Hematology Portfolio

REVLIMID® and POMALYST®/IMNOVID® backbone in MM • Advance REVLIMID® as maintenance treatment post ASCTNHL - iNHL

VIDAZA®

MDSAML

ISTODAX®

CTCL, PTCLPOMALYST®/IMNOVID®

• Advance REVLIMID® as maintenance treatment post ASCT

Continuing in Lymphoma• Data on CC-122 phase II in 2016

MMCC-486 (oral aza)MDSAML

Sotatercept (ACE-011)MDSDi d bl kf i

• Data for RELEVANCE®, REMARC and AUGMENTTM expected beginning in 2017

Advancing AG-221 and luspatercept into phase III programsDiamond blackfan anemiabeta-thalassemiaLuspatercept (ACE-536)MDSbeta-thalassemia

AG-221Heme malignancies

Advancing AG-221 and luspatercept into phase III programs

Initiate “Immuno-Hematology” programs with durvalumab

37

Heme malignancies

Robert Hershberg, MD PhDSVP, Immuno-Oncology

Celgene’s Immuno-Oncology Portfolio Addresses Multiple Aspects of the Anti-Tumor Immune Response

39

Celgene’s Immuno-Oncology Portfolio Addresses Multiple Aspects of the Anti-Tumor Immune Response

Durvalumab (MEDI4736)IMiDs®

VTX 2337IMiDs® VTX-2337CAR-TSutro 2.0

ABRAXANE®

CC-486

IMiDs®Anti-CD47VTX-2337NK cells (CCT)

VTX-2337

IMiDs®

40

PD-1/PD-L1 Targeting Agents are Dominant Assets in the I/O Landscape

• Unprecedented value expected in multiple oncology indications

• Nivolumab (BMS) and Pembrolizumab (Merck) approved

• Atezolizumab (MPDL3280A) (Roche) and durvalumab (AZ) likely to be approved in next 24 months

• Avelumab (Pfizer) in clinical development

• Impressive data across multiple tumor types, and intense competition are solidifying the position of this target and these drugs with patientsare solidifying the position of this target and these drugs with patients and physicians

4141

Emerging Themes and Key Questions with Checkpoint Inhibitors

• Most patients don’t respond to these agents in isolation, instead requiring combination therapy.

What are the most important combination agents that will be used in the near and mid-term?

• PD-1 and/or PD-L1 expression alone are inadequate to predict p q presponse

What characteristics define responsive patients and how will this inform optimal combination and innovation in the space?p p

• Multiple molecules beyond PD-1 and CTLA-4 control T-cell checkpoints

Whi h f th t l ill lif i diWhich of these controls will amplify responses in non-responding patients?

4242

ABRAXANEABRAXANE®® Delivers Activity without CorticosteroidsDelivers Activity without Corticosteroids

® Cremophor is a registered trademark of BASF.® nab is a registered trademark of Celgene Corporation.

References: Gardner et al. Clin Cancer Res. 2008;14(13):4200-4205.Desai et al. Clin Cancer Res. 2006;12:1317-1324.

43

REVLIMID® is an Immunomodulatory Drug

DC, dendritic cell; NK, natural killer.

44

Citations in appendix

IMiDs® and PD-1/PD-L1 Inhibitors May Have Complementary and Synergistic Effects

Effect IMiDs® PD-1 / PD-L1 axis blockade1. Recruitment/↑ number Expansion of T cells, CTLs, NK cells and1. Recruitment/↑ number

of immune cellsExpansion of T cells, CTLs, NK cells and NKT cells

2. Induction/ priming of ↑ Response to vaccines ↑ response to vaccines2. Induction/ priming of T cells/ immune response

↑ Response to vaccines↑ DC antigen presentation/T cell priming↑ Antibody priming

↑ response to vaccines↑ T cell priming

3. T cell polarisation ↑ Th1 polarization/cytokines ↑ Th1 polarization/cytokines

4. Effector cell function ↑ CTL activity↑ Th cell activity↑ NKT cell activity↑ NK cell activity↑ NK cell tumor killing/ADCC

Re-activation of CTL and Th cell activityRe-activation of NK cell activityEnhanced B-cell antibody production

5. PD1/PD-L1 axis activity

↓ PD-1 expression on T-cells↓ PD-1 expression on MM cells

Reversal of PD-1–induced T cell anergyReactivation of CTL and Th cell activityRe-activation of NK cell activity

45

Cereblon Modulates Immune Response

THALOMID® REVLIMID® POMALYST®/IMNOVID®

CC-122 CC-220 Future

CEREBLON

Substrates(Common, Unique, Partially shared)

REVLIMID® modulates T cell biology (T cell synapse, IL-2 d ti ) d NK bi l i IKAROS d AILOS2 production) and NK biology via IKAROS and AILOS regulation

Novel CELMoDs™ are being developed with potent,

46

g p p ,directed immunomodulatory properties

Combining Epigenetic Modulation and Checkpoint Blockade

Hypothesis:Hypothesis: • Azacitidine hypomethylates/

reactivates genes necessary for recognition of tumor cells by immune

CC-486

g yeffectors

– PD-L1 expression– Tumor antigen expression– HLA Class 1 expression– Type-1 Interferon expression

• Blockade of PD-1 pathway in bi ti ith CC 486Anti PD1

X

combination with CC-486 may improve anti-tumor activity

Anti-PD1

4747

Celgene’s Campaign in Immuno-Oncology

Complementarity

Conviction

CommitmentCommitment

48

Advancing Checkpoint Combinations with Celgene Assets

Atezolizumab - Roche• Two randomized pivotal studies with ABRAXANE® in combination in NSCLC enrolling• Phase III trial with ABRAXANE® in 1st-line metastatic triple negative breast cancer to begin enrollment soon

Nivolumab – Bristol-Myers Squibb • Phase I trial with ABRAXANE® in multiple solid tumors

Pembrolizumab - Merck• Phase I/II trials with REVLIMID® or POMALYST®/IMNOVID® in RRMM enrolling• Phase I/II trial with ABRAXANE® in NSCLC to begin enrollment soon• Trials with CC-486 in NSCLC and ovarian cancer planned

49

Emerging Data Suggest that PD-1/PD-L1 Pathway is Important in Hematologic Malignancies

Multiple Myeloma

• In vitro and in vivo experiments show significant up-regulation of PD-L1 in ndMM and rrMM patients1

Myeloid

• Increasing evidence for the importance of immunotherapeutic approaches in AML and MDS2-8AML and MDS

– Allogeneic transplant as curative approach in AML and high-risk MDS patients– Increased PD-L1 expression on AML and MDS cells in patients post-treatment with HMA– Increased PD-L1 expression on AML stem cells and in residual disease (MRD+)

1. Gorgun GT et al. Clin CancerRes 2015 [Epub ahead of print]2. Kondo A, et al. Blood. 2010;116(7):1124-1131.

3. Tamura H. J Nippon Med Sch. 2010;77(1):45-47 [abstract].

50

pp ( ) [ ]4. Zhang L, et al. Blood. 2009;114(8):1545-1552.

5. Krönig H, et al. Eur J Haematol. 2013;92:195-203. 6. Zhou Q, et al. Blood. 2010;116(14):2484-2493.

7. Yang H, et al. Leukemia. 2013. [Epub ahead of print].8. Yang H, et al. Blood. 2013;122(21):2767 [abstract].

50

Emerging Data Suggest that PD-1/PD-L1 Pathway is Important in Hematologic Malignancies

Lymphomas

• Impressive single agent response data with anti-PD1 antibodies in Hodgkin Lymphoma

– 9p amplification in Reed-Sternberg cell includes PD-L1/PD-L2 locus1

I i id f li ti f i th ti h• Increasing evidence for application of immunotherapeutic approaches in lymphomas

– Allogeneic transplant as curative approach in indolent lymphoma– Increased PD-1 expression on tumor infiltrating T-lymphocyes post treatment

with R22,3

– Early clinical data with PD-1 in DLBCL, PD-1 plus rituximab in FL suggest clinical activity4

1 Yamamoto et al Blood 2008; 111; 3220

51

1. Yamamoto et al. Blood. 2008; 111; 32202. Myklebust JH et al. Blood. 2013; 121:1367

3. Fowler et al., Lancet Oncology, 20154. Westin JR et al. Lancet Oncol. 2014;15:69-77

51

Celgene Poised for “Immuno-Hematology” Leadership

• Recently announced collaboration with AstraZeneca/MedImmune for durvalumab

• Celgene will lead clinical development of combination trials in hematologic indications

• Celgene will be working closely with MedImmune on translational aspects of studies and will have

t b d biliti d d t iaccess to broad capabilities and data in emerging I/O space

Celgene has competitive advantage in hematology• I/O backbone therapies across hematology: Rd, Pd, R²• Scientific/Clinical expertise in indications that will be the focus for checkpoint inhibitor development in hematology: MM NHL MDS/AML

52

checkpoint inhibitor development in hematology: MM, NHL, MDS/AML• Existing hematology commercial infrastructure

Anticipated Clinical Development Strategy for Durvalumab: Combinations in Hematology

Combinations with

First Wave

Multiple Myeloma REVLIMID® and POMALYST® /

IMNOVID®

Non-Hodgkin Lymphoma

CLL

Combinations with IMiDs®, mAbs and targeted therapiesCLL

MDS/AML

targeted therapies

Combinations withMDS/AML Combinations with CC-486 and VIDAZA®

5353

Anticipated Clinical Development Strategy for Durvalumab: Combinations in Hematology

Combinations with Combinations with

First Wave Second Wave

Multiple Myeloma REVLIMID® and POMALYST® /

IMNOVID®

Combinations with pipeline assets and

novel therapies

Non-Hodgkin Lymphoma

CLL

Combinations with IMiDs®, mAbs and targeted therapies

Combinations with pipeline assets and

novel therapiesCLL

MDS/AML

targeted therapies

Combinations with

novel therapies

Combinations with i li t dMDS/AML Combinations with

CC-486 and VIDAZA® pipeline assets and novel therapies

5454

The Complexity of the Tumor Microenvironment

55

W Fridman et al. Nature Rev Can 12, 298-306 (2012) doi:10.1038/nrc3245

55

Additional I/O Assets at Celgene

• Anti-CD47 (CC-90002) monoclonal antibody– First-in-class molecule targeting novel macrophage biology in cancer

Advanced to Phase 1 in multiple tumor types– Advanced to Phase 1 in multiple tumor types

• Toll-like receptor 8 agonist (motolimod, VentiRx)– First-in-class small molecule stimulator of Innate Immunity (macrophages, NK)– 2 large randomized Phase II studies (ovarian, head/neck) to read out in 2016

• Novel IMiDs®/CELMoDs™ (CC-122)– Existing clinical assets are immunomodulatory, stimulate T cells and NK cells– CRBN biology leading to novel immunomodulators

• SUTRO/Novel Biologics– Collaborative and internal efforts leading to 2nd generation, novel checkpoint

inhibitors (“bi-specifics” and other approaches)

• InfrastructureInfrastructure– I/O TCoE operational in Seattle– Focus on translational and computational aspects of I/O to enable current and

next generation products

56

Dedicated to Immuno-Oncology;Pioneering “Immuno-Hematology”

Existing assets are mechanistically unique andExisting assets are mechanistically unique and complementary to checkpoint inhibitors

ABRAXANE®, REVLIMID®, CC-486

Aggressively pursuing a broad development Aggressively pursuing a broad development program with durvalumab in multipleprogram with durvalumab in multipleprogram with durvalumab in multiple program with durvalumab in multiple

hematological malignancies in collaboration hematological malignancies in collaboration with AZ/MEDIwith AZ/MEDI

Emerging assets extend and complement Emerging assets extend and complement

57

beyond current Tbeyond current T--cell checkpoint inhibitorscell checkpoint inhibitors

Jackie Fouse, PhDPresident, Global Hematology & Oncology

On-Track to Deliver 2020 Hematology and OncologyTargets

>$17B

15%CAGR

$7.45B

2014 2017E 2020E

59

Hematology Oncology

New ABRAXANE® Opportunities Accelerate Momentum Through 2020

Expected Growth OpportunitiesExpected Growth Opportunities>$2 2

Sales ($B)>$2.2Growth from Existing Portfolio:

• Market share and geographic expansion of ABRAXANE® in NSCLC and metastatic pancreatic cancer 14%

CAGR $1.917%CAGRpancreatic cancer

New Indications & Opportunities:• ABRAXANE® late stage trials in:

• Adjuvant pancreatic cancer

CAGR $1.9CAGR

$0.85Adjuvant pancreatic cancer

• Additional segments of NSCLC

• Triple negative breast cancer

• Neoadjuvant breast cancer

2014 2017E 2020E

j

60

ABRAXANE® Label Expansions; New Opportunities

Market Share in “MPACT Population” Patients Approaching 50%

60%Pancreatic 1st line Stage IV Regimen ShareDE NOVO METASTATIC “MPACT Population”

49.5%

40%

50%

33.1%

20%

30%

13.8%

1.7%1.8%

0%

10%

Abraxane gemcitabine** FOLFIRINOX 5FU + other all otherAbraxane gemcitabine FOLFIRINOX 5FU other all other

61

Source: IntrinsiQ Report: Diag Combo LOT Stage Monthly_pancreatic (exocrine) carcinoma; Apr R3M pre-projected patients: 116; projected patients: 2928

**Gemcitabine includes monotherapy and combination other than with ABRAXANE®

Market Share in Squamous 1st-Line NSCLC Stable

50%mNSCLC Squamous 1st line Molecule Share

40%

16.9%20%

30%

6 9%

0%

10%

0%

paclitaxel gemcitabine Abraxane docetaxelb i b l ti ib i b i l b

Source: IntrinsiQ Report: Diag Drug Met Status Pathology 3MRA (Progression Line)_lung cancer (non-small cell); Apr R3M pre-projected patients: 146; projected patients: 3669

62

bevacizumab erlotinib ramucirumab nivolumab

Market Share in 2nd-line HER2- ER/PR+ Share Rebounds

50%

2nd line HER2- ER/PR+ MBC

30%

40%

12 1%

20%

30%

12.1%

0%

10%

Abraxane* paclitaxel mono docetaxel monocapecitabine mono gemcitabine mono Halaven monoCombinations

Source: IntrinsiQ Report: Celgene HRS Her-2 Combo Met Status Monthly (Maintenance Herceptin and No Afinitor or Ibrance Mono )_met 2nd line; Apr R3M pre-projected patients: 97; projected patients: 2447

ABRAXANE®*=nab-paclitaxel alone or in combinationCombinations = Gem-carbo or Paclitaxel combinations

63

New Opportunity with Emerging Data in Triple Negative mBC

50%

Triple Negative mBC All Lines Share

30%

40%

20%

30%

7.4%

0%

10%

capecitabine mono paclitaxel mono carboplatin - gemcitabinegemcitabine mono Abraxane* docetaxel mono

64

Halaven mono taxane combo

Source: IntrinsiQ Report: Celgene HRS Her-2 Combo Met Status Monthly (Maintenance Herceptin and No Afinitor or Ibrance Mono ); Apr R3M pre-projected patients: 184; projected patients: 4638

ABRAXANE®*=nab-paclitaxel alone or in combination

64

Additional Oncology Opportunities Accelerate Momentum Through 2020

Expected Growth OpportunitiesExpected Growth Opportunities>$2 2

Sales ($B)Oncology Upside Potential Through 2020Oncology Upside Potential Through 2020>$2.2

Growth from Existing Portfolio• Market share and geographic expansion of

ABRAXANE® in NSCLC and metastatic pancreatic cancer

14%CAGR $1.917%CAGR

ABRAXANE® in anti-PD-1 / anti-PD-L1 combinationspancreatic cancer

New Indications & Opportunities:• ABRAXANE® late stage trials in:

• Adjuvant pancreatic cancer

CAGR $1.9CAGR

Demcizumab approval in non-small cell lung and pancreatic cancers

$0.85• Adjuvant pancreatic cancer

• Triple negative breast cancer

• Neoadjuvant breast cancer

Additional segments of NSCLC

VTX-2337 approval in ovarian and SCCHN

2014 2017E 2020E

• Additional segments of NSCLCCC-486 approval in solid tumors

65

ABRAXANE® Label Expansions; New Opportunities

New Hematology Opportunities Expected to Accelerate Growth Through 2020

Expected Growth OpportunitiesExpected Growth Opportunities Sales ($B)

12%14%

Growth from Existing Portfolio:• REVLIMID® approved for NDMM in U.S. and

Europe• Duration and market share gains for

>$14.8

$13 012%CAGR 14%CAGR

Duration and market share gains for REVLIMID® and POMALYST®/IMNOVID®

New Indications & Opportunities:• REVLIMID® in novel combos in myeloma $6 6

$13.0

y• REVLIMID® for NHL

New Product Introductions:• CC-486 (oral azacitidine) in MDS and AML

$6.6

2014 2017E 2020E

• Luspatercept in beta-thalassemia• AG-221 in IDH2 mutant AML

66

Existing Products

Label Expansions; New Products

Additional Hematology Opportunities Accelerate Momentum Through 2020

Expected Growth OpportunitiesExpected Growth Opportunities Sales ($B)Hematology Upside Potential Through 2020Hematology Upside Potential Through 2020

12%14%

Growth from Existing Portfolio• REVLIMID® approvals for NDMM in U.S.

and Europe• Duration and market share gains for

>$14.8

$13 0

• Full impact of REVLIMID® and POMALYST®/IMNOVID® treatment duration

• REVLIMID® for non-del 5q in Europe 12%CAGR 14%CAGR

Duration and market share gains for REVLIMID® and POMALYST®


$13.0• REVLIMID® for maintenance in CLL

• Broader and earlier adoption of REVLIMID® in lymphomasy

• REVLIMID® for NHL


$6.6• Approval for luspatercept in MDS

• Earlier than expected approval for AG-221 in R/R AML (IDH2 mutations)

2014 2017E 2020E

• Sotatercept or Luspatercept in beta-thalassemia

• AG-221 (IDH2 mutant AML)

in R/R AML (IDH2 mutations)

• Approval for AG-120 in R/R AML (IDH1 mutations)

• Approval for CC-122 in DLBCL, CLL or MM

67

Existing Products


pp ,

Additional Hematology Opportunities Accelerate Momentum Through 2020

Expected Growth OpportunitiesExpected Growth Opportunities Sales ($B)Hematology Upside Potential Through 2020Hematology Upside Potential Through 2020

12%14%

Growth from Existing Portfolio• REVLIMID® approvals for NDMM in U.S.

and Europe• Duration and market share gains for

>$14.8

$13 0

• Full impact of REVLIMID® and POMALYST®/IMNOVID® treatment duration

• REVLIMID® for non-del 5q in Europe 12%CAGR 14%CAGR

Duration and market share gains for REVLIMID® and POMALYST®


$13.0• REVLIMID® for maintenance in CLL

• Broader and earlier adoption of REVLIMID® in lymphomasFirst approval y• REVLIMID® for NHL


$6.6• Approval for luspatercept in MDS

• Earlier than expected approval for AG-221 in R/R AML (IDH2 mutations)

ppfor durvalumab

possible by 2020

2014 2017E 2020E

• Sotatercept or Luspatercept in beta-thalassemia

• AG-221 (IDH2 mutant AML)

in R/R AML (IDH2 mutations)

• Approval for AG-120 in R/R AML (IDH1 mutations)

• Approval for CC-122 in DLBCL, CLL or MM

68

Existing Products


pp ,

Generating Strong Franchise Momentum

Key Drivers for 2020 Targets in PlaceKey Drivers for 2020 Targets in Place

MidMid-- to Lateto Late--Stage Pipeline AdvancingStage Pipeline AdvancingLeading to Data Readouts in 2016Leading to Data Readouts in 2016

Investing in Next Generation Drugs toInvesting in Next Generation Drugs toSustain High Growth Beyond 2020Sustain High Growth Beyond 2020

69

g yg y

Questions & Answers

Moderator: Peter KelloggggEVP and CFO

Panelists: Jackie Fouse, PhDPresident, Global Hematology & Oncology

Jay Backstrom, MDSVP, Global Hematology & Oncology Clinical R&D

Rob Hershberg, MD PhDRob Hershberg, MD PhDSVP, Immuno-Oncology

70

ASCO 2015 Investor EventMay 31, 2015

Reconciliation Tables

013 6,36

2.3

131.

6 6,49

3.9

340.

4 2,22

6.2

1,68

4.5

262.

8 17

1.1

4,68

5.0

1,80

8.9

22.0

(91.

6) (7

3.9)

1,66

5.4

215.

5 1,44

9.9

1.75

1.

68

827.

7 86

0.6

une

18,

-one

Ende

d

2014

20

7,56

3.8

6

$

106.

6

7,67

0.4

6

385.

9

2,43

0.6

2

2,

027.

9

1

258.

3

48.7

5,15

1.4

4

2,51

9.0

1

28.2

(176

.1)

(4

3.7)

2,32

7.4

1

327.

5

1,99

9.9

1

$

2.49

$

2.39

$

802.

7

836.

0

te o

f inc

orpo

ratio

n on

Ju

on a

nd e

ffec

t a tw

o-fo

r-an

d pe

r sha

re a

mou

nts

Twel

ve-M

onth

Per

iods

ED

ecem

ber 3

1,

arie

sf I

ncom

e

$

$

$

$

ties

y am

ende

d its

cer

tific

at

5.0

milli

on to

1.1

50 b

illio

Acc

ordi

ngly

, all

shar

e a

ock

split

.

T

tion

and

Subs

idia

ted

Stat

emen

ts o

fna

udite

d)ce

pt p

er s

hare

dat

a)

ing

amor

tizat

ion

ofss

ets)

t stra

tive

ntan

gibl

e as

sets

s, ne

tns

es

com

e, n

et

net es hare

:(1)

1) ts &

mar

keta

ble

secu

rit

gs quity

r app

rova

l, th

e C

ompa

nynu

mbe

r of

com

mon

sto

ck fr

om 5

75an

ding

com

mon

sto

ck. A

ect t

he im

pact

of t

he s

to

Cel

gene

Cor

pora

ten

sed

Con

solid

at (Un

(In m

illio

ns, e

xc

t pro

duct

sal

eshe

r rev

enue

Tota

l rev

enue

st o

f goo

ds s

old

(exc

ludi

acqu

ired

inta

ngib

le a

sse

arch

and

dev

elop

men

tlin

g, g

ener

al a

nd a

dmin

ism

ortiz

atio

n of

acq

uire

d in

quisi

tion

rela

ted

char

ges

Tota

l cos

ts a

nd e

xpen

erat

ing

inco

me

eres

t and

inve

stm

ent i

ncer

est (

expe

nse)

her i

ncom

e (e

xpen

se),

n

ome

befo

re in

com

e ta

xe

ome

tax

prov

ision

t inc

ome

t inc

ome

per c

omm

on s

hB

asic

Dilu

ted

ight

ed a

vera

ge s

hare

s:(

Bas

icD

ilute

d

lanc

e sh

eet i

tem

s:C

ash,

cas

h eq

uiva

len t

Tota

l ass

ets

Shor

t-ter

m b

orro

win

gLo

ng-te

rm d

ebt

Tota

l sto

ckho

lder

s' eq

Follo

win

g st

ockh

olde

r20

14, t

o in

crea

se th

e n

auth

orize

d sh

ares

of c

stoc

k sp

lit o

f its

out

sta

pres

ente

d he

rein

refleC

Con

de

72

Net

Oth

Cos

Res

Selli

Am

Acq

Ope

Inte

Inte

Oth

Inco

Inco

Net

Net

Wei

Bal (1)

Reconciliation Tables

8.4

for t

helv

e-m

onth

ility-

wei

ghte

d

.

9.9

8.5

4.7

5.8

- 2.6

- 2.8

1.1

0.0

2.3)

3.1

.10

.98

Dec

embe

r 31,

201

4 an

d $9

8to

talin

g $4

47.6

for t

he tw

e31

, 201

3.

hang

es in

est

imat

ed p

roba

bil

gani

zatio

n.es

ter P

harm

aceu

tical

s, In

cla

).uc

este

r, A

brax

is, A

vila

and

se

o ed

2014

2013

1,99

9.9

1,44

9$

26.2

18

196.

5

144

45

3.6

57

5

129.

2

-

224.

9

162

25

.0

-

258.

3

262

48.7

171

-

8 0

(263

.7)

(3

0 2

3,

098.

6

2,

563

$

3.86

3 .$

3.71

2.$

thre

e-m

onth

per

iod

ende

d D

sed

com

pens

atio

n ex

pens

e h

perio

d en

ded

Dec

embe

r 3lla

bora

tion

arra

ngem

ents

.t r

ecor

ded

as a

resu

lt of

ch

tribu

tions

to a

non

-pro

fit o

rgof

Pha

rmio

n C

orp.

, Glo

uce

omic

s R

esea

rch,

Inc.

(Avi

ld

to th

e ac

quisi

tions

of G

lou

S. G

AAP,

this

pre

ss r

elea

sve

stor

s an

d m

anag

emen

t d

tren

ds th

at fa

cilit

ate

tion.

The

se a

djus

ted

tion

to, b

ut n

ot a

s a

AP. W

e ty

pica

lly e

xclu

de

ic o

pera

tions

and

that

do

er c

ompa

nies

may

def

ine

wel

ve-M

onth

Per

iods

End

eD

ecem

ber 3

1,

ries

t Inc

ome

$

on

(1)

(1)

(2)

(3)

(1)

(4)

ts(5

)

nsid

erat

ion

(6)

(7)

(8)

$

$

$

nse

tota

ling

$128

.4 fo

r the

th1,

201

3. E

xclu

de s

hare

-bas

325.

8 fo

r the

twel

ve-m

onth

earc

h an

d de

velo

pmen

t col

men

t (IP

R&

D) i

mpa

irmen

t

tion

to m

ake

mat

chin

g co

ntr

acqu

ired

in th

e ac

quisi

tions

A

brax

is) a

nd C

elge

ne A

vilo

ngen

t con

sider

atio

n re

late

d

ed in

acc

orda

nce

with

U.S

hat w

e be

lieve

pro

vide

inv

pera

ting

perf

orm

ance

and

ect t

o pr

ojec

ted

info

rmat

uld

be c

onsi

dere

d in

add

itac

cord

ance

with

U.S

. GAA

not b

elie

ve a

ffec

t our

bas

ino

n-re

curr

ing

item

s. O

thT w

ratio

n an

d Su

bsid

iar

AA

P to

Adj

uste

d N

et, e

xcep

t per

sha

re d

ata)

P ustm

ents

:s

sold

(exc

ludi

ng a

mor

tizat

ioin

tang

ible

ass

ets)

:ed

com

pens

atio

n ex

pens

e

d de

velo

pmen

t:ed

com

pens

atio

n ex

pens

eol

labo

ratio

n ex

pens

em

pairm

ent

al a

nd a

dmin

istra

tive:

ed c

ompe

nsat

ion

expe

nse

of c

ontin

gent

obl

igat

ion

of a

cqui

red

inta

ngib

le a

sset

elat

ed c

harg

es, n

et:

fair

valu

e of

con

tinge

nt c

on

(exp

ense

), ne

tng

ass

et im

pairm

ent

x ad

just

men

tste

d

mm

on s

hare

- A

djus

ted

tmen

ts:

base

d co

mpe

nsat

ion

expe

npe

riod

ende

d D

ecem

ber 3

1D

ecem

ber 3

1, 2

014

and

$3nt

pay

men

t exp

ense

for r

ese

cess

rese

arch

and

dev

elop

mla

ted

to C

C-2

92.

men

t of a

con

tinge

nt o

blig

atiza

tion

of in

tang

ible

ass

ets

aA

brax

is B

ioSc

ienc

e In

c. (A

es in

the

fair

valu

e of

con

tin

ncia

l inf

orm

atio

n pr

epar

est

ed fi

nanc

ial m

easu

res

thin

form

atio

n re

latin

g to

op

en p

erio

ds a

nd w

ith r

esp

are

non-

GAA

P an

d sh

o unf

orm

atio

n pr

epar

ed in

as

that

man

agem

ent d

oes

nde

finiti

on o

f unu

sual

or

diff

eren

t way

s.

Cel

gene

Cor

por

Rec

onci

liatio

n of

GA

(In m

illio

ns,

73

Net

inco

me

- GA

AP

Bef

ore

tax

adju

Cos

t of g

oods

o

f acq

uire

d i

Shar

e-ba

se

Res

earc

h an

d

Sh

are-

base

Upf

ront

co

IPR

&D

im

Sel

ling,

gen

era

Shar

e-ba

se

Se

ttlem

ent

Am

ortiz

atio

n o

Acq

uisit

ion

re

C

hang

e in

f

Oth

er in

com

e

Non

-ope

rati n

Net

inco

me

tax

Net

inco

me

- A

djus

Net

inco

me

per c

omB

asic

Dilu

ted

Expl

anat

ion

of a

djus

t(1

)Ex

clud

e sh

are-

th

ree-

mon

th p

pe

riod

ende

d (2

)Ex

clud

e up

fron

(3)

Excl

ude

in-p

roc

cas

h flo

ws

rel

(4)

Excl

ude

settl

em(5

)Ex

clud

e am

orti

(G

louc

este

r),

(6)

Excl

ude

chan

ge

In a

dditi

on to

fina

nal

so c

onta

ins

adju

sw

ith s

uppl

emen

tal i

com

pari

sons

bet

we

finan

cial

mea

sure

s su

bstit

ute

for,

the

ince

rtai

n G

AAP

item

sno

t mee

t the

GAA

P th

ese

mea

sure

s in

dR

Appendix

Citations for REVLIMID® Mechanism of Action

1. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumor activity of rituximab in vivo. Br J Haematol. 2007;140:36-45.

2. Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharm Exp Ther. 2003;3051222-1232.

3. Haslett PA, Hanekom WA, Muller G, Kaplan G. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis. 2003;187:946-955.

4. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006;108:618-621.

5. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.

6. Tai YT, Li XF, Catley L, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005;65:11712-11720.

7. Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14:4650-4657.

8. Baz R, Dimopoulos M, Richardson P, et al. Lenalidomide-based therapy leads to improvement of humoral immunity in relapsed or refractory multiple myeloma patients who respond to the therapy. Haematologica. 2009;94:159[Abstract 0395].

9. Noonan KA, Ferguson A, Emerling L, et al. Lenalidomide augments immune responses to Prevnar® vaccination in relapsed myeloma patients: implications for cancer and infectious vaccines. Blood (ASH Annual Meeting Abstracts). p y p p ( g )2009;114:739-740[Abstract 1864].

75

Lymphoma Prevalence

Disease overview

DLBCL (aggressive) Diffuse large B-cell lymphoma 300K

PREVALENCETYPE

FL (indolent) Follicular lymphoma 190K

MCL (aggressive) Mantle cell lymphoma 30KB cell MCL (aggressive) Mantle cell lymphoma 30K

Other indolent lymphomas Marginal zone, WM etc. 210KNHL

B-cell

Other aggressiveNHL Burkitt etc. 155K

CTCL (indolent) Cutaneous T-cell lymphoma 10KC C ( do e t) Cuta eous ce y p o a 0

PTCL (aggressive) Peripheral T-cell lymphoma 35K

T t l P l 930K

T-cell

76

Notes: 10-Year Prevalence across US, EU5, and Japan (2015)Source: Kantar Health

Total Prevalence 930K

Celgene Pipeline

77

Celgene Pipeline

78

Celgene Pipeline

79

Celgene Pipeline

80

Celgene-Sponsored Trials in Presentation

Patient Population Adjuvant Therapy in Surgically Resected Pancreatic Cancer

Locally Advanced Pancreatic Cancer

T i l NPANC-003

Trial NameAPACT

PANC-007

Phase III II

Target Enrollment 800 110Target Enrollment 800 110

DesignArm A: ABRAXANE® (125 mg/m2) / Gemcitabine (1000 mg/m2) D 1, 8 and 15 for 6 28-day cyclesA B G it bi (1000 / 2) D 1 8 d

ABRAXANE® (125 mg/m2) D 1,8 and 15 / Gemcitabine (1000 mg/m2) D 1, 8, and 15 for 6

28-day cyclesSubjects who complete 6 cycles w/o PD or

unacceptable toxicities can:gArm B: Gemcitabine (1000 mg/m2) D 1, 8 and

15 for 6 28-day cycles. Continue on therapyGo on to chemoradiation

Go on to surgical intervention

Primary Endpoint Disease Free Survival Time to Treatment FailurePrimary Endpoint Disease Free Survival Time to Treatment Failure

Status Trial enrolling Trial enrolling

81


Patient PopulationPts with Advanced Pancreatic Cancer Who Have Cholestatic

Hyperbilirubenemia

Trial Name PANC-004

Phase I

Target Enrollment 60

Design

ABRAXANE® at 3 different doses (75, 100 and 125 mg/m2) on D 1, 8, and 15 / Gemcitabine at 3different doses (600, 800 and 1000 mg/m2) on D

1, 8 and 15 for a 28-day cycleDesign Subject with three different levels of bilirubin are

evaluatedBilirubin level > 1.5 x ULN to 2 x ULN, > 2 x ULN

to 3 x ULN and > 3 x ULN to 5 x ULN

MTD, Pharmacokinetics, Apparent volume of distribution at the steady state and Apparent total

Primary Endpointdistribution at the steady state and Apparent total

body clearance

St t T i l lliStatus Trial enrolling

82


Patient Population

Advanced NSCL Cancer in the Elderly

First Line NSCLC Subjects With ECOG

PS2Second Line Advanced Nonsquamous NSCLC

NSCL 005 NSCL 004Trial Name

NSCL-005Abound.70+

NSCL-004Abound.PS2

Abound.2L

Phase IV II II

Target 284 50 160Target Enrollment 284 50 160

Arm A: ABRAXANE® (100 mg/m2) D 1, 8, and 15 / Carboplatin (AUC=6 mg*min/mL) D 1 of a 21-day cycle

ABRAXANE® (100 mg/m2) D 1 and 8 / Carboplatin (AUD=5

Arm A: ABRAXANE® (100 mg/m2) D 8 and 15 / CC-486

(200 mg) daily D 1-4 for a 21-day cycle

Designmg min/mL) D 1 of a 21 day cycle

Arm A: ABRAXANE® (100 mg/m2) D 1, 8, and 15 / Carboplatin (AUC=6 mg*min/mL) D 1 of a 28-day cycle

and 8 / Carboplatin (AUD=5 mg*min/mL) D 1 of a 21-day

cycle

y yArm B ABRAXANE® (100

mg/m2) D 1 and 8 for a 21-day cycle

Primary Endpoint

Percentage of participants who will experience either peripheral

neuropathy or myelosuppressionSafety Progression Free Survival

Status Trial Enrolling Trial Enrolling Trial EnrollingStatus Trial Enrolling Trial Enrolling Trial Enrolling

83


Patient Population First Line Stage IIIB / IV Squamous NSCLC

Trial NameNSCL-003

Abound sqmAbound.sqm

Phase III

Target Enrollment 260

Design

Arm A: Induction – ABRAXANE® (100 mg/m2) D 1, 8 and 15 / Carboplatin (6 mg/min/ml) D 1 of a 21-day cycle; Maintenance – ABRAXANE® (100 mg/m) D

1 and 8 of a 21-day cycle or Best supportive careArm B: Induction – ABRAXANE® (100 mg/m2) D 1, 8 and 15 / Carboplatin (6

mg/min/ml) D 1 of a 21-day cycle; Maintenance – Best supportive careg ) y y ; pp

Primary Endpoint Progression Free Survival

Status Trial enrolling

84


Patient Population First-Line Triple Negative Metastatic Breast Cancer

tnAcity™Trial Name

tnAcity™ABI-007-MBC-001

Phase II/III

Target Enrollment 240/550Target Enrollment 240/550

Phase IIArm A: ABRAXANE® 1(25mg/m2) / Gemcitabine

(1000 mg/m2) D 1 and 8 – 21-day cycleArm B: ABRAXANE® (125mg/m2) / Carboplatin

DesignAUC 2 IV, D 1 and 8 – 21-day cycle

Arm C: Gemcitabine (1000 mg/m2) / Carboplatin AUC 2 IV, D 1 and 8 – 21-day cycle

Phase IIIArm 1: Selected phase II ABRAXANE® armp

Arm 2: Gemcitabine (1000 mg/m2) / Carboplatin AUC 2 IV, D 1 and 8 – 21-day cycle

Primary Endpoint Progression Free Survival

Status Trial enrolling

85

asco 2015 investor event

Documents